Aspira Women's Health CSO/COO Ryan Phan resigns, transitions to advisor

Aspira Women's Health Inc.

Dr. Ryan Phan resigns as Chief Scientific & Operating Officer effective Sept 15, 2023, becomes advisor Sept 16, 2023.
Consulting agreement pays $20,000/month through Jan 15, 2024; options continue vesting during term.
$50,000 retention bonus forgiven if Phan remains employed through Dec 31, 2023.
Phan to continue as CLIA lab medical director until Jan 15, 2024.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ryan Phan

Chief Scientific and Operating Officer

AWHL · Aspira Women's Health Inc.

Effective: 2023-09-15
Filed: September 12, 2023, 7:59 PM ET

On August 3, 2023, Dr. Ryan Phan, the Chief Scientific and Operating Officer of Aspira Women’s Health Inc., (the “Company), notified the Company that he will resign from these roles with the Company effective September 15, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ryan Phan resigned as Chief Scientific and Operating Officer at Aspira Women's Health Inc..

Action: resigned
Role: Chief Scientific and Operating Officer

Exact text from the filing

On August 3, 2023, Dr. Ryan Phan, the Chief Scientific and Operating Officer of Aspira Women’s Health Inc., (the “Company), notified the Company that he will resign from these roles with the Company effective September 15, 2023.

View on SEC.gov

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-23-000077

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.